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ABSTRACT 
Sedimentation equilibrium and size-exclusion chromatography experiments on Mycobacterium 
tuberculosis hypoxanthine-guanine phosphoribosyltransferase (MtHGPRT) have established the 
existence of this enzyme as a reversibly associating mixture of dimeric and tetrameric species in 0.1 
M Tris-HCl−0.012 M MgCl2, pH 7.4. Displacement of the equilibrium position towards the larger 
oligomer by phosphate signifies the probable existence of MtHGPRT as a tetramer in the biological 
environment. These data thus add credibility to the relevance of considering enzyme function in the 
light of a published tetrameric structure deduced from X-ray crystallography. Failure of 5-phospho-
α-D-ribosyl-1-pyrophosphate (PRib-PP) to perturb the dimer−tetramer equilibrium position 
indicates the equivalence and independence of binding for this substrate (the first to bind in an 
ordered sequential mechanism) to the two oligomers. By virtue of the displacement of the 
equilibrium position towards dimer that is affected by removing MgCl2 from the Tris-HCl buffer, it 
can be concluded that divalent metal ions, as well as phosphate, can affect the oligomerization. 
These characteristics of MtHGPRT in solution are correlated with published crystal structures of 
four enzyme−ligand complexes.  
 
Keywords:  Mycobacterium tuberculosis; hypoxanthine−guanine phosphoribosyltransferase; 
enzyme activity; oligomers; three-dimensional structure; structural biology 
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1. Introduction  
 
 Hypoxanthine−guanine phosphoribosyltransferase (HGPRT), a key enzyme in the purine 
salvage pathway, has received considerable attention as a potential target for chemotherapeutic 
drugs against several parasitic [1−4] and bacterial [5, 6] human pathogens because of their reliance 
upon this pathway for the synthesis of the 6-oxopurine nucleoside monophosphates required for 
DNA/RNA production. Recently, it has been shown that prodrugs of compounds that inhibit 
Mycobacterium tuberculosis (Mt) HGPRT arrest the growth of Mt in tissue culture [6]. This finding 
strongly suggests that MtHGPRT is a target for drug development against human tuberculosis. The 
reaction catalyzed by this enzyme is shown in Fig. 1A, which indicates the requirement of a 
divalent metal ion for catalysis to proceed. X-ray crystal structures show that magnesium ions are 
present in the active site of the 6-oxopurine PRTases under three conditions: (i) when coordinated to 
the hydroxyl groups of the ribose ring of the first substrate, 5-phospho-α-D-ribosyl-1-pyrophosphate 
(PRib-PP); (ii) when coordinated to the phosphoryl oxygen atoms of the reaction product, PPi e.g. 
when in complex with tight binding transition state analogs [7, 8]; and (iii) when coordinated to the 
tight binding acyclic nucleoside phosphonate inhibitors (ANPs) [1, 2]. However, in the unliganded 
structure of human HGPRT, no divalent metal ion is present. In contrast, a magnesium ion is 
coordinated to the side chains of the two completely conserved acidic residues (E103 and D104) in 
the active site of Escherichia coli (Ec) HPRT in the absence of ligand [9]. This led to the hypothesis 
that, for EcHPRT, magnesium ions may also be needed to stabilize the enzyme prior to catalysis [9].  
 Four crystal structures of MtHGPRT have been determined [6], one in the form of a ternary 
complex with GMP and PPi, and the others as binary complexes with three tight-binding inhibitors 
(Fig. 1B) − all acyclic nucleoside phosphonates (ANPs) [6]. For the ternary MtHGPRT−GMP−PPi 
complex and the binary complex with inhibitors 1 (2-[3-(guanin-9-yl)-2-(2-
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bis(hydroxyphosphoryl)ethoxy)propoxy]ethyl)phosphonic acid) and 3 (2-((2-((2-(hypoxanthine-9-
yl)ethyl)(2-phosphonoethyl)amino)ethyl)(2-phosphonoethyl)amino)ethyl)phosphonic acid), the 
enzyme structure is tetrameric whereas, for the complex with inhibitor 2 (2-((2-(guanin-9-
yl)ethyl)(2-((2-hydroxyethyl)(2- phosphonoethyl)amino)ethyl)amino)ethyl)phosphonic acid), the 
structure is dimeric. These findings require rationalization with a subsequent size-exclusion 
chromatography study from which a dimeric state for MtHGPRT in solution has been inferred [11].  
  
Fig. 1. (A) Synthesis of the 6-oxopurine nucleoside monophosphates, IMP and GMP, 
by MtHGPRT. R = -H (hypoxanthine); -NH2 (guanine). Xanthine is not a substrate for 
MtHGPRT [6, 10]. (B) Chemical structures of three ANP inhibitors where G is 
guanine and Hx is hypoxanthine. The acyclic phosphonate moiety is attached to the N9 
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atom of the purine ring. The crystal structures of MtHGPRT in complex with these 
inhibitors have been determined [6]. 
 
 In this physicochemical investigation of the solution characteristics of MtHGPRT, 
sedimentation equilibrium and size-exclusion chromatography studies under conditions (0.1 M 
Tris−HCl−MgCl2, pH 7.4 at 22°C) similar to those in the earlier study [11] have revealed the 
existence of a dimer−tetramer equilibrium that is susceptible to displacement by ligand-binding.  
 
2. Materials and methods 
 
2.1. Purification of recombinant MtHGPRT 
 
 Recombinant MtHGPRT was purified and stored at −70°C in 0.1 M Tris−HCl buffer (pH 7.4 
supplemented with 12 mM MgCl2 and 0.2 mM PRib-PP, conditions under which it is stable for 
more than six months [6]. SDS-PAGE and mass spectrometry showed the enzyme preparation to be 
homogeneous with a subunit molecular mass of 23,874 Da, in agreement with the calculated value. 
Enzyme concentrations are based on an extinction coefficient ( ) of 8.2 at 280 nm [6]. Stored 
aliquots of the enzyme were thawed before dialysis for 15−20 hours against the appropriate buffer 
prior to size-exclusion chromatography, sedimentation equilibrium and enzyme kinetic studies. 
Although Tris−HCl buffers are identified by their pH at room temperature (22°C), the actual pH at 
the lower temperature used in size-exclusion chromatography and sedimentation experiments 
(9−10°C) is slightly higher (∼ 7.7) because of the enthalpy of Tris ionization.  
 
2.2. Size-exclusion chromatography  
 
%1
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MtHGPRT (100 µL, 2.2−2.8 mg/mL) in 0.1 M Tris-HCl, pH 7.4 (pH measured at 22°C), 0.1 M 
Tris-HCl, 12 mM MgCl2, pH 7.4 (pH measured at 22°C) or 0.01 M phosphate buffer (pH 7.4) 
supplemented with 12 mM MgCl2 was subjected to size-exclusion chromatography at 9°C on a 
Superdex 200 column (1 × 30 cm) pre-equilibrated with the same buffer and operated at a flow rate 
of 0.5 mL/min. The column eluate was monitored spectrophotometrically at 280 nm and apparent 
molecular molecular masses were calculated on the basis of elution volumes for chymotrypsinogen, 
ovalbumin and bovine serum albumin as standard proteins. In one experiment, the column effluent 
was monitored by a DAWN Heleos II light-scattering detector coupled with an Optilab TrEX 
refractive index detector (Wyatt Technology, Santa Barbara, CA) to provide elution profiles in terms 
of molecular mass as well as protein concentration.  EcHPRT was also subjected to gel filtration in 
0.01 M Tris-HCl, 12 mM MgCl2, 1 mM DTT, pH 7.4. The presence of DTT is essential for 
maintaining active enzyme due to the formation of disulfide bonds. EcHPRT is completely inactive 
in the absence of reducing agents. MtHGPRT, on the other hand, contains only one cysteine residue 
per subunit and does not require the presence of reducing agents to maintain activity.  
 
2.3. Sedimentation equilibrium studies 
 
 Purified MtHGPRT in dialysis equilibrium with 0.1 M Tris-HCl, pH 7.4, 0.1 M Tris-HCl, 12 
mM MgCl2, pH 7.4, or 0.01 M phosphate buffer (pH 7.4) supplemented with 12 mM MgCl2 was 
subjected to sedimentation for 40 h in a Beckman XL-I analytical ultracentrifuge operating at 
15,000 rpm and 10°C. Rayleigh interference records of the resulting equilibrium distributions were 
analyzed in terms of the expression for a single non-associating macromolecular solute, namely 
 
    (1) )]2/()()1(exp[)()()()( 222 RTrrvMrJrJrjrJ FsFa −−=+= ωρ
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where j(r), the recorded fringe count (taken as zero at the air−liquid meniscus), is the difference 
between the interferometric counterpart, J(r), of protein concentration at radial distance r and that, 
J(ra), at the air−liquid meniscus (ra): J(rF) is the value of J(r) at a chosen reference radial position rF 
(7.05 cm in these instances). The buoyant molecular mass, , as well as J(ra) and J(rF) 
were determined as curve-fitting parameters by nonlinear regression analysis of the dependence of 
j(r) upon the exponential term in Eq. (1), where ω is the angular velocity of rotation, T the absolute 
temperature and R the universal gas constant. In that regard the consistent return of an extremely 
small estimate of J(ra) established that these sedimentation equilibrium distributions were 
essentially of meniscus-depletion design [12]; and hence that j(r) ≈ J(r). Calculation of the protein 
partial specific volume ( ) as 0.738 mL/g from its amino acid composition, and also the relevant 
buffer density (ρs), by means of SEDENTERP subroutines [13] then allowed calculation of the 
apparent protein molecular mass (M) from the estimate of its buoyant counterpart. 
 On the grounds that the apparent molecular mass returned for MtHGPRT in Tris-
HCl−MgCl2 buffer (72 kDa) was intermediate between those of dimer (48 kDa) and tetramer (96 
kDa), estimates of the association constant (X, L/g) for a dimer−tetramer equilibrium (2A  C) as 
well as cA(rF), the weight-concentration of monomer at the reference radial position, were obtained 
as curve-fitting parameters by nonlinear least-squares curve-fitting of the sedimentation equilibrium 
distributions to the expression 
 
  
      +   (2) 
 
)1( ρvM −
v
)]2/()()1(exp[)(33.3/)( 222 RTrrvMrcrJ FAFA −−= ωρ
)]2/()()1(2exp[)}({ 22222 RTrrvMrcX FAFAapp −− ωρ
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where the factor of 3.33 converts concentrations from Rayleigh interference fringes to the weight-
concentration (g/L) scale [14]. 
 
2.4. Enzyme kinetic studies 
 
    Enzyme kinetic experiments were conducted at 25°C in accordance with the continuous 
spectrophotometric assay described previously [1]. The mechanism of MtHGPRT has been shown 
to be ordered-sequential [11], as found for the human enzyme [15]. Because the interaction of 
interest concerned the effect of phosphate on the binding of first substrate (PRib-PP) in the 
ordered−sequential mechanism, reaction mixtures comprised fixed concentrations of guanine (59 
µM) and enzyme (2.83 µg/mL) as well as 80−1250 µM PRib-PP in Tris-HCl−12 mM MgCl2 buffer, 
pH 7.4, or the same buffer supplemented with either 8 or 42 mM phosphate.  
 
3. Results  
 
 As noted in the Introduction, this investigation has arisen from a report [11] that refutes the 
solution-state relevance of the tetrameric structure deduced by X-ray crystallography for the ternary 
complex of HPRT with pyrophosphate and GMP as well as for binary complexes with inhibitors 1 
and 3 (Fig. 1B) [6]. That repudiation of a tetrameric structure for MtHGPRT was based on 
characterization of the enzyme by zonal size-exclusion chromatography on Superdex 200, an 
endeavor that seemingly favored a dimeric state for MtHGPRT in 0.05 M Tris-HCl, 0.2 M NaCl 
(pH 7.4). This aspect of the solution behavior of the M. tuberculosis enzyme is considered first.  
 
3.1. Size-exclusion chromatography of MtHGPRT 
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 Initially, a standard empirical calibration procedure based on elution volumes for serum 
albumin, ovalbumin and chymotrypsinogen (inset Fig. 2A)  [16] and an elution profile study for 
EcHPRT, a stable tetramer with a molecular mass of 84 kDa were performed on a Superdex 200 
column (1 × 30 cm)  (Fig. 2A) [9]. The elution volume for EcHPRT (lowermost open symbol in the 
inset to Fig. 2A) diverges from the linear calibration plot. This relative retardation is consistent with 
enzyme migration governed by a superimposed protein−matrix interaction on the size-exclusion 
process, the phenomenon responsible for the retarded elution of lysozyme from Sephadex matrices 
[17]. Vertical displacement of the elution volumes for the other three protein standards to account 
for enzyme retardation leads to the revised calibration plot (open symbols and solid line) (inset Fig. 
2A). The absorbance (A280) elution profile obtained for MtHGPRT equilibrated with 0.1 M Tris-HCl 
buffer containing 12 mM MgCl2 on this column is presented in Fig. 2B. Based on the calibration 
plot, an apparent molecular mass of 55 kDa for this peak is in agreement with the earlier findings of 
this sample in Tris-HCl at neutral pH [11], with the major peak being in a dimeric state (the 
molecular mass of the monomer is 24 kDa) (see Section 2.1). Thus, EcHPRT elutes as a single 
tetramer in 0.1 M Tris-HCl, 12 mM MgCl2, 1 mM DTT, pH 7.4 whereas MtHGPRT elutes as three 
different oligomeric species. DTT is absent from the buffers containing MtHGPRT as there is only 
one cysteine residue per subunit and this enzyme does not undergo oxidation in the absence of 
reducing agents. The trimodal nature of the elution profile (Fig. 2B) clearly requires further 
investigation. Consideration of all three peaks to reflect MtHGPRT is confirmed in Fig. 2C, which 
presents the corresponding elution profile for enzyme in 10 mM phosphate buffer (pH 7.4) 
supplemented with 12 mM MgCl2. The redistribution of solute within the elution profile clearly 
precludes heterogeneity as the source of the trimodality observed in Fig. 2B. Whereas phosphate 
effects a displacement within the elution profile in a manner symptomatic of higher molecular mass, 
the removal of MgCl2 from the Tris-HCl buffer has the opposite effect (Fig. 2D) with the major 
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species now dimeric in accordance with the literature. We therefore conclude that MtHGPRT in the 
Tris−chloride−Mg2+ comprises a mixture of oligomeric states coexisting in a self-association 
equilibrium that is relatively slowly attained on the time-scale of chromatographic separation 
(approx. 20 mins), because instantaneously attained equilibrium would result in an asymmetric but 
unimodal reaction zone [18].  
 
 In all three elution profiles, the majority of the activity is located in the higher molecular 
weight forms, which are tetrameric or dimeric. In Fig. 2B, 62% of the total activity is located in 
fractions 14 and 15, in Fig. 2C, >90% of the activity is in fractions 13 and 14, while in Fig. 2D, 
75% of the activity is found in fractions 15 and 16. Thus, both tetrameric and dimeric forms of the 
enzyme are active after column chromatography and that the specific activity of the tetramer 
appears higher than that of the dimer. 
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Figure 2. Elution profiles obtained by zonal size-exclusion chromatography for EcHPRT 
and MtHGPRT on a Superdex 200 column in different buffers. (A) E. coli HPRT in 0.1 
M Tris-HCl, 12 mM MgCl2, 1 mM DTT, pH 7.4. Inset column calibration with serum 
albumin, ovalbumin and chymotrypsinogen (broken line), correction due to vertical 
displacement (solid line). (B) MtHGPRT in 0.1 M Tris-HCl, 12 mM MgCl2,, pH 7.4. (C) 
MtHGPRT in 0.01 M phosphate, 12 mM MgCl2, pH 7.4. N.D. = not determined. (D) 
MtHGPRT in 0.1 M Tris-HCl, pH 7.4. The elution profile as well as the Vo for each of 
these two peaks is unchanged in 0.1 M Tris-HCl, pH 7.4 containing 0.2 M NaCl.  
 
3.2. Sedimentation equilibrium studies of MtHGPRT 
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 To further analyse the self-association of MtHGPRT solutions of the enzyme (2 mg/mL) 
were subjected to centrifugation at 15,000 rpm and 10°C are summarized in Fig. 3. Analysis of the 
distribution for enzyme in 0.1 M Tris−HCl−MgCl2 buffer (Fig. 3A) according to Eq. (1) yielded an 
apparent molecular mass (± 2 SD) of 72.4 (± 0.6) kDa for the putative single solute, a value that 
increased to 96.0 (± 0.5) kDa in the corresponding analysis of the distribution (Fig. 3B) for 
MtHGPRT in 0.01 M phosphate buffer (also supplemented with MgCl2). The latter is considered to 
reflect existence of the enzyme as the 96 kDa tetramer in phosphate, whereas the molecular mass 
obtained in the Tris−HCl buffer is taken to reflect enzyme in dimer−tetramer association 
equilibrium: the molecular mass deduced from the meniscus region of these distributions of 
essentially meniscus-depletion design [12] signifies a 45-kDa entity (dimer) as the smallest 
MtHGPRT species present in the Tris-HCl−MgCl2 environment.  
 The specific activity of the enzyme in 0.1 M Tris-HCl, 12 mM MgCl2, pH 7.4, at the 
beginning and the end of all the sedimentation equilibrium runs, was unchanged. At the end of the 
run the specific activity was 1228 U/mg-1 (assayed in 0.1 M Tris-HCl, 12 mM MgCl2, pH 7.4). 
When assayed in 0.01 M phosphate, 12 mM MgCl2, pH 7.4, the specific activity was 2524 U/mg-1, 
demonstrating that the activity increases in the presence of phosphate. For the sedimentation 
equilibrium runs in 0.01 M phosphate, 12 mM MgCl2, pH 7.4, the enzyme was first dialysed into 
this buffer for 20 hour before commencement of the runs. The S.A. then remained constant at 11 
000 U/mg-1 (assayed in 0.01 M phosphate, 12 mM MgCl2, pH 7.4). This data shows that the most 
active form of the enzyme occurs in the presence of magnesium and phosphate and the oligomeric 
state under these conditions is tetrameric.  
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 Sedimentation equilibrium distributions signifying a molecular mass of 45.4 (± 0.3) kDa, 
consistent with a dimeric state for MtHGPRT, was obtained by eliminating MgCl2 from the Tris-
HCl buffer by exhaustive dialysis (Fig. 3C). The S.A., in the presence and absence of 0.2 M NaCl, 
was similar with values of 812 units mg-1 (assayed in 0.1 M Tris-HCl, 12 mM MgCl2, pH 7.4) and 
500 units mg-1 (assayed in 0.01 M phosphate, 12 mM MgCl2, pH 7.4). Thus, this dimeric state has a 
low S.A. in the absence of magnesium ions but is stable during the time course of the gel filtration 
and also the sedimentation equilibrium runs. Dilution into phosphate in the assay buffer (0.01 M 
phosphate, 12 mM MgCl2, pH 7.4) did not result in activation suggesting that this dimeric state, 
which occurs when excess magnesium ions are removed, is unable to be rapidly activated by 
phosphate and magnesium. This differs from the situation above when the enzyme is kept in high 
concentrations of magnesium ions.  MtHGPRT in 0.1 M Tris-HCl, pH 7.4 maintains its activity of 
500 units mg-1 (see above) but on dilution into 0.01 M phosphate, pH 7.4, the activity is completely 
lost over a 24 hour period. This supports the proposition that phosphate alone cannot activate the 
enzyme and that magnesium ions are also required. 
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Fig. 3. Sedimentation equilibrium distributions obtained by centrifuging solutions of 
MtHGPRT in (A) 0.1 M Tris-HCl −0.012 M MgCl2 buffer, (B) 0.01 M phosphate−0.012 
M MgCl2 buffer, and (C) 0.1 M Tris-HCl devoid of the MgCl2. Centrifugation of all 
samples was at 15,000 rpm and at 10°C. 
 
 
 Subject to validity of the assumption that the distribution observed for enzyme in the 
Tris−chloride buffer (Fig. 3A) does reflect the attainment of chemical as well as sedimentation 
equilibrium, the application of Eq. (2) yields an estimate of 4.2 (± 0.2) L/g for the apparent 
association constant for dimer−tetramer interconversion. In keeping with the molecular mass 
estimates from the other two distributions, the corresponding estimate was infinite for enzyme in 
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phosphate [cA(rF) indistinguishable from zero], and zero in the magnesium-free environment [cA(rF) 
indistinguishable from the total concentration at the reference radial position]. 
 The fact that molecular mass estimates were unchanged by including PRib-PP in the 
solutions subjected to sedimentation equilibrium (Fig. 4) signifies the equivalence and 
independence of PRib-PP binding to the dimeric and tetrameric states of MtHGPRT in situations 
where they coexist. Furthermore, the binding of the second substrate analog 9-deazaguanine, 
together with Mg2+ and PRib-PP to form the ternary complex, also has no effect on the measured 
apparent molecular mass. Preferential interaction of PRib-PP with either the dimeric or tetrameric 
state would lead to displacement of the dimer−tetramer equilibrium and hence to the observation of 
allosteric binding behavior dependent upon enzyme concentration [19]. Importantly, these findings 
justify the interpretation of published enzyme kinetic results [11] for this reaction in 0.05 M 
Tris−0.2 M NaCl buffer (pH 7.4) in terms of hyperbolic saturation curves and description in terms 
of expressions for an ordered sequential mechanism with ternary complex formation involving a 
single site for each substrate − an assumption also evident from the use of the enzyme-subunit 
concentration to characterize catalysis [11]. 
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Fig. 4. Comparison of the average molecular masses of MtHGPRT in complex with PRib-
PP in the Tris−HCl and phosphate buffers pertaining to Fig. 3. 
 
 Although the presence of phosphate ensures the existence of MtHGPRT as tetramer, this 
ligand was not included in the solution that yielded the crystals of enzyme−pyrophosphate−GMP 
complex used for structure determination. Instead, displacement of the dimer−tetramer equilibrium 
in favor of the tetrameric state would have resulted from the molecular crowding effect [20−25] of 
PEG-8000 (200 g/L) included in the buffer to promote crystallization [6]. The logic of that 
statement is illustrated by the following considerations. 
 The thermodynamic association constant X2 is defined by the expression 
 
 )/()/)(/( 22222 ACappACAC XccX γγγγ ==       (3) 
 
where appX 2 , the appropriate ratio of species weight-concentrations ci, differs from the 
thermodynamic association constant because of the activity coefficient term [20,26]. From 
theoretical consideration of thermodynamic nonideality on the statistical-mechanical basis of 
excluded volume [27,28], the two activity coefficients are defined by  
 
 ...]///2exp[ +++= PPAPCCACAAAAA McBMcBMcBγ  ≈ exp(BAPcP/MP)  (4a) 
 ...]///2exp[ +++= PPCPAAACcCCCC McBMcBMcBγ  ≈ exp(BAPcP/MP)  (4b) 
 
where Bij denotes the osmotic second virial coefficient for physical interaction between species i 
and j; and where species P is an inert molecular crowding agent (PEG-8000). For the present system 
the approximate forms of Eqs. (4a) and (4b) apply because the range of protein concentration is 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 17
sufficiently small to justify the neglect of thermodynamic activity in the absence of crowding agent  
(γA ≈ γC ≈ 1), whereupon the parameter deduced from a sedimentation equilibrium distribution for 
MtHGPRT in unsupplemented buffer (4.2 L/g; see above) is effectively X2. Under those 
circumstances the ratio of the two experimental dimerization constants becomes [20,26] 
 
 ]/)2exp[(/ 22 PPCPAPapp McBBXX −≈       [5] 
 
where, for current comparative purposes, it suffices to assign magnitudes to BAP and BCP on the 
basis of spherical geometry for all species and hence the expression 
 
 
3)()3/4( jiAij RRNB += pi         [6] 
 
in which the effective radius of dimer (RA) has been taken as 3 nm, a plausible value for a 48 kDa 
species inasmuch as the effective radius of ovalbumin (a 44 kDa protein) is 2.9 nm [29]; and that of 
tetramer as RC = 21/3RA = 3.8 nm: Avogadro’s number (NA) is included in Eq. (6) to convert the 
virial coefficient from a molecular to a molar basis.  
 Combination of the relationship [24,30] 5.00292.0 PP MR =  nm for polyethylene glycol with 
the molecular mass (8000 Da) of the current crowding agent leads to an estimate of 2.6 nm for RP 
and hence to values of 443 and 661 L/mol for BAP and BCP respectively. The consequent estimate of 
277 for 22 / XX
app
 obtained from Eq. (5) for the predicted effect of 200 g/L PEG-8000 on the 
HGPRT dimer−tetramer equilibrium leads to a predicted appX 2  of 1165 L/g. Combination of this 
value with the enzyme concentration of 8 g/L used for the hanging-drop crystallization experiments 
in the statement of mass conservation, 822 =+ AA
app ccX , gives rise to an estimate of 0.08 g/L for cA; 
and hence of 99% for the proportion of MtHGPRT present in the tetrameric state. Although these 
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calculations do not apply directly to the conditions used for the crystallization process, they do 
suffice to identify tetramer as the likely predominant state of the enzyme; and hence provide a 
rational basis for the deduction of a tetrameric structure for MtHGPRT by X-ray crystallography, 
which only accesses the structure of the predominant species.  
 
3.3. Enzyme kinetic studies 
 On the grounds that the interaction of phosphate with MtHGPRT displaces the 
dimer−tetramer equilibrium in favor of the tetrameric state, it was of interest to determine whether 
this preferential phosphate binding to produce a tetramer has any effect on enzyme function. 
Enzyme kinetic studies with 2.83 µg/mL MtHGPRT were conducted in 100 mM Tris-HCl−12 mM 
MgCl2 at a fixed concentration (59 µM) of guanine and a variable concentration of PRib-PP 
(50−1250 µM). Phosphate  (either 8 mm or 42 mM) was included in some reaction mixtures.  
Results in the presence of phosphate (solid symbols) are shown as Hanes’ plots in Fig. 5, which also 
includes corresponding results from duplicate experiments in the absence of phosphate  (open 
symbols). Activation is signified by the decrease in slope (the reciprocal of maximal velocity for the 
fixed guanine concentration) and the increase in abscissa intercept (− ) for both experiments 
with phosphate. This activation could result indirectly from phosphate attachment to MtHGPRT 
sites away from the active-site center − interactions that not only facilitate tetramer formation (Fig. 
4) but also promote conformational changes that trigger enhanced enzyme activity (Fig. 5).   
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Fig. 5. Hanes plots of initial velocities for MtHGPRT containing a fixed concentration of 
guanine (59 µM) and PRib-PP as the variable substrate in the 0.1 M Tris-HCl-12 mM 
MgCl2 buffer supplemented with either 8 mM () or 42 mM () phosphate. Open 
symbols refer to duplicate experiments in the 0.1 M Tris-HCl−12 mM MgCl2 buffer (with 
no phosphate added). 
 
 Inasmuch as 10 mM phosphate suffices to displace the dimer−tetramer equilibrium 
completely in favor of the larger oligomer (Fig. 3B), we conclude that MtHGPRT is likely to 
function as a tetramer (rather than a dimer) in its biological environment − the oligomeric state 
exhibited by the human variant of this enzyme [1] as well as EcHPRT [9]. Our earlier 
considerations of MtHGPRT in terms of the tetrameric structure deduced by X-ray crystallography 
for the ternary complex of enzyme, pyrophosphate and GMP [6] are thereby deemed to be justified. 
 
 
 
4. Discussion  
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 This investigation of the solution behavior of MtHGPRT has established the existence of this 
enzyme in a Tris−chloride−Mg2+ enviroment at neutral pH as a mixture of dimeric and trimeric 
states in a reversible association equilibrium. [11]. This is displaced towards the higher oligomer 
(tetramer) by the binding of phosphate ions and also by molecular crowding in the concentrated 
environment required to effect crystallization. An intriguing feature of the quaternary structure of 
the 6-oxopurine PRTases is the potential for different arrangements of the four subunits. The 
difference between MtHGPRT and human HGPRT resides in the orientation of the dimer pairs (A/B 
and C/D) to make the tetramer − a factor clearly evident by comparing the location of a large mobile 
loop (approx. 20 amino acid residues in length) that is proposed to close over the active site during 
catalysis [8] (Fig. 6). In MtHGPRT and EcHPRT, the large mobile loop in the dimer pairs face each 
other [6, 9], whereas the loops are found at the extremities of the tetramer in human HGPRT [1] 
(Fig. 6).  
 
 
 
Fig. 6.  Connolly surface for the crystal structure of the tetramer in (A) MtHGPRT (PDB 
code: 4RHX.inhibitor 3, Fig. 1B) [6]) and (B) human HGPRT in the presence of an aza-
ANP inhibitor (PDB code: 4RAO), 9-[(N-Phosphonoethyl-N-phosphonomethoxyethyl)-
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2- aminoethyl]hypoxanthine [1]. In both structures, the visible region of the large mobile 
loop, residues 90-106 in MtHGPRT and 101-117 in human HGPRT, is coloured red.  
Each polypeptide chain in the MtHGPRT tetramer is identified by the letters A-D. 
 
 Apart from EcHPRT the only other 6-oxopurine PRTase that has a tetrameric arrangement 
similar to MtHGPRT is Thermoanaerobacter tengcongensis HGPRT [34]. The rationale as to why 
the Mt and EcHPRT enzymes have evolved to form such a subunit arrangement is unknown but, 
since such a configuration is observed in an enzyme of thermophilic origin, the need to maintain a 
high level of structural stability appears to be a contributing factor. 
 
The crystal structure of MtHGPRT in complex with inhibitor 2 (Fig. 1B) reveals that the 
dimer interface is between subunits A and B [6]. One possible reason for the need for this interface 
is the hydrogen bond between the side chains of K65 and D109 in the adjacent subunit (Fig. 7A). 
The corresponding inter-subunit hydrogen bond is also present in the crystal structure of EcHPRT 
in the unliganded form and also in the presence of IMP (Fig. 7C) [9]. In comparison, the inter-
subunit bond only forms in human HGPRT [1,8] when a ligand, able to occupy the pyrophospate-
binding pocket, is present (Figs. 7B, D). This is because the side chain of K68 has to rotate to 
vacate this space. In the absence of crystal structures of unliganded  MtHGPRT or in the absence of 
compounds without a PPi moiety, it is unknown whether this enzyme resembles the bacterial 
enzyme or the human enzyme in this respect. In other words, is the side chain of the basic residue  
fixed as in EcHPRT or is it flexible as in human HGPRT? However, the crystal structure of 
MtHGPRT does suggest that the most stable dimeric sructure of this enzyme in solution involves 
subunits A and B, and that this structure is the precursor of the tetramer.  
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Fig. 7.  The different intra- and inter-subunit interactions involving the positively charged moieties 
of the highly conserved basic residue (K65 in MtHGPRT, K68 in human HGPRT and R45 in 
EcHPRT).  (A) MtHGPRT in complex with inhibitor 2 and inhibitor 3; (B) human HGPRT with an 
inhibitor, 9-[(N-Phosphonoethyl-N-phosphonomethoxyethyl)-2-aminoethyl]hypoxanthine [1]; (C) 
EcHPRT with IMP (coloured by element) and unliganded (coloured yellow); and (D) human in 
absence of ligand [31]. 
 
 
 Displacement of the reversible association equilibrium for MtHGPRT towards the dimeric 
state by the removal of Mg2+ (Figs. 2D, 3C and 4) signifies that this divalent metal ion interacts 
preferentially with tetramer. However, the displacement of the dimer−tetramer equilibrium in favor 
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of the lower oligomeric state by the removal of metal ion signifies the presence of Mg2+-binding 
sites on the apoenzyme. This conclusion finds parallel in studies of EcHPRT, for which the strength 
of the interaction with metal ion suffices for the detection of magnesium ions in the substrate-free 
crystal structure. In this structure, it is coordinated to the completely conserved amino acid side 
chains of E103 and D104 [9]. The greater strength of the Mg2+ interaction for EcHPRT presumably 
accounts for its detection as a tetramer in size-exclusion chromatography and sedimentation 
equilibrium studies of the apoenzyme in 0.1 M Tris-HCl-0.012 M MgCl2 buffer, pH 7.4 [9].  In 
contrast, magnesium ions are only found in the crystal structures of human HGPRT in complex with 
inhibitors or transition state analogs [1, 8,35]. The location of the acidic residues to which it is most 
likely that the divalent metal ion would be coordinated is removed from any subunit interface.  
Thus, it can only be deduced that binding of the metal ion triggers movement of flexible loops 
allowing inter-subunit bonds to form thus stabilizing the oligomeric structure. 
 As well as refuting the earlier size-exclusion chromatography evidence for the existence of 
MtHGPRT as a dimer in Tris−HCl at neutral pH [11], this study has also provided a rational 
explanation for that conclusion, which reflected interpretation of the elution volume for enzyme in 
terms of a standard calibration plot for globular proteins. The additional interaction of MtHGPRT 
with the chromatographic matrix leads to slower migration than that predicted solely on the basis of 
size exclusion. Indeed, in view of the sedimentation equilibrium result for enzyme in a Mg2+-free 
environment (Figs. 3C, 4), it would seem that the dimeric form of MtHGPRT exhibits an elution 
volume similar to that for the slowest-migrating peak in Fig. 2A − an elution profile that comprises 
a trimodal reaction zone encompassing the entire region between the elution volumes of dimer and 
tetramer. 
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 Although MtHGPRT in Tris-HCl−MgCl2 buffer comprises a mixture of dimeric and 
tetrameric states in association equilibrium, the failure of PRib-PP to perturb that equilibrium (Fig. 
4) signifies the equivalence and independence of this substrate in binding to the two oligomers and, 
possibly, an independence of catalysis upon the oligomeric state of the enzyme. In that regard the 
observation of preferential phosphate-binding to produce the tetramer (Fig. 4) signifies the likely 
existence of MtHGPRT as a tetrameric structure in the biological environment and hence adds 
credibility to the relevance of considering enzyme function in the light of the tetrameric X-ray 
structure. Molecular crowding caused by PEG-8000 in the crystallization buffer is another factor 
that can contribute to tetramer formation. We base these conclusions on a series of biophysical 
measurements, all with their own specific limitations and with the enzyme outside its native 
environment within the cell. Although all of our structural and kinetic data is consistent, effects of 
the very low concentration of enzyme in the spectrophoto assays, and the potential for change in 
oligomeric state at high temperatures ( > 25 C) cannot be easily assessed. 
 
Conclusions 
 The environment in which MtHGPRT finds itself clearly effects the oligomeric state and its 
activity in solution. The most active form of the enzyme is tetrameric and the formation of this 
structure is induced by different ligands. The dimeric structure is also active though  ~50% of that 
of the tetramer. Removal of magnesium from the environment of the enzyme not only affects the 
quaternary structure but also further reduces the activity of the enzyme to less than half again of the 
activity in the presence of this ion.  Divalent metal ions are prevalent in all biological systems so it 
is deduced, that in nature, MtHGPRT can exist as dimers or tetramers with one being favoured over 
the other in different environments. In the host macrophage the Mycobacterium tuberculosis 
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bacterium is subjected to stress, so possibly requires a more stable and active form of the enzyme 
(i.e. tetrameric form) whereas, outside the macrophage, the dimeric form might be sufficient for 
survival.  It is proposed that differences in quaternary structure and overall fold of the enzyme can 
be exploited for selective drug design over the human counterpart. 
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• Mycobacterium tuberculosis hypoxanthine-guanine 
phosphoribosyltransferase  (MtHGPRT) is an established target for anti-TB 
drug development. 
 
• Solution studies have confirmed MtHGPRT is a reversibly associating mixture 
of dimeric and tetrameric species, a finding that is in agreement with 
observations based on crystal structures 
 
• The presence or absence of divalent metal ions, as well as phosphate, can 
affect the oligomerization state of the enzyme. 
 
